Clinical Policy: Paltusotine (Palsonify)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.755 alerts
Get alerted when Policy CP.PHAR.755 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing limits, prior authorization expectations, and approval durations for Palsonify (paltusotine) for adult members with acromegaly across Commercial, HIM, and Medicaid lines of business.
Policy redirects to trial of Mycapssa and one of lanreotide or generic octreotide acetate LAR (or Sandostatin LAR Depot if generic is unavailable) as step therapy prior to Palsonify.
Illinois HIM requests are exempt from certain step therapy requirements per IL HB 5395 effective 1/1/2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.